Pharmaceuticals Archives

ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26

ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Mirabegron settlement; CDMO revenue ramp-up in H2 FY27; biosimilar launches on schedule.
Outcome: US revenue grows 8–10% YoY, driven by specialty and generics volume. EBITDA margins stabilize at 23–25%. India and International Markets sustain 15–20% growth. Net debt reduces to ₹2,500Cr by FY28 as cash flows improve. GLP-1 captures 10–15% market share in India.

DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26

DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.

TORNTPHARM – Q3 FY26 Earnings Call – 13-Feb-26

TORNTPHARM’s base case projects 12–14% CAGR driven by Brazil/U.S. execution and JB integration, with margins expanding to 33–34% by FY29. Outcomes hinge on GLP-1 timing, Germany resolution, synergy capture, and cost discipline, as structural tailwinds offset cyclical pricing pressures

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Ozempic launches in Brazil by late FY27; (2) JB synergies realize as guided (INR 400–450Cr by FY29).
Outcome: Brazil grows at 12–15% CAGR (ex-Semaglutide); U.S. hits $200M revenue by FY27 (20% CAGR). JB’s margin improves to 30% by FY28. Germany stabilizes by Q2 FY27; alternate supplier onboarded in 3 quarters.
Implications: Topline grows at 12–14% CAGR; EBITDA margins expand to 33–34% by FY29. Net debt/EBITDA targets achieved; interest expense declines to INR ~50Cr by FY29. FCF turns positive by FY28.

BIOCON – Q3 FY26 Earnings Call – 13-Feb-26

Topline growth hinges on GLP-1/biosimilar launch execution and insulin capacity scaling, while margins and cash flow depend on Syngene’s CRDMO recovery and debt reduction pace—model 12–18% revenue CAGR with 25–28% EBITDA as base, but skew risks to downside on regulatory delays.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Liraglutide/semaglutide launch in EU/Canada by late 2026; insulin capacity doubles on schedule, capturing 15–20% market share in interchangeable segments. Biosimilars grow 15–18% YoY (new launches offset legacy erosion); generics sustain 20%+ growth. Trigger: Regulatory clarity + successful tech transfers. Outcome: Group revenue grows 12–15% YoY; EBITDA margins expand to 26–28%.

GLENMARK – Q3 FY26 Earnings Call – 2-Feb-26

GLENMARK’s topline hinges on Flovent/Monroe execution and RYALTRIS scale—12–20% growth bandwidth; bottomline leverages innovation margin uplift (23–28% EBITDA); margins rebound to 68–72% gross if respiratory/oncology launches deliver, but FX, litigation, and Monroe risks warrant 15–20% discount to consensus.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Flovent approved Q4 FY26; (2) Aumolertinib launches H2 FY27.

Topline: 12–15% consolidated revenue growth (India 18–20%, EM 15–18%). RYALTRIS hits $200M by FY28.
Bottomline: EBITDA margin expands to 25% (Flovent gross margin uplift, operating leverage). Net cash ~INR 800Cr.
Margins: Gross margin recovers to 68–70% (respiratory mix shift).

SUNPHARMA – Q3 FY26 Earnings Call – 31-Jan-26

Sun Pharma’s topline growth is milestone-dependent and exposed to US generics structural decline, while bottom-line resilience hinges on tax rate stabilization and R&D productivity; margins face near-term pressure from launch costs but could inflect in FY28 if innovative scales and OAI risks abate—model 31–33% EBITDA as the new range.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key variables: (1) OAI resolutions by late FY27, enabling 2–3 major ANDA launches; (2) Unloxcyt/LEQSELVI hit $200M run rate by FY28.
Outcome: Revenue grows 10–12% (ex-FX), with India/Semaglutide contributing 40% of incremental sales. EBITDA margins stabilize at 31–32%; EPS grows 6–8% on tax headwinds. Implication: In-line with consensus; 22–24x PE sustained.

CIPLA – Q3 FY26 Earnings Call – 23-Jan-26

Cipla’s topline resilience hinges on US pipeline execution (respiratory/peptides) and India chronic therapy growth, while margins face near-term pressure from R&D lumpiness and Lanreotide disruption; FY27 EBITDA recovery to 21%+ requires flawless launch sequencing and cost normalization.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Lanreotide resumes in H1 FY27; two respiratory launches in H1 FY27 (one sole generic).
Generic Victoza and one peptide launch in FY27; Yurpeak traction sustains (~₹150 crore/month).
Result: US revenue stabilizes at $130–150M/quarter; EBITDA margin recovers to 20–21%; FY27 guidance maintained at 21%.

SYNGENE – Q3 FY26 Earnings Call – 23-Jan-26

SYNGENE’s topline faces near-term headwinds from single-product concentration, but diversification efforts (BMS, Bayview, clinical trials) could stabilize revenue by FY27; margins hinge on CDMO utilization and cost discipline, with EBITDA recovery lagging revenue by 12–18 months. Cash flow remains resilient but vulnerable to CAPEX overruns or prolonged revenue drag.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Librela stabilizes by H2 FY27, with partial revenue recovery (50% of lost run-rate). CDMO utilization reaches 60–70% in Mangalore/Bayview, driven by 1–2 new large-molecule contracts. Research services grow 8–10%, supported by biotech funding. FY27 revenue flat to +2%, EBITDA margins 23–25%.
Trigger: Zoetis resolves product issues; Syngene secures $20–30M annual CDMO contracts.

LAURUSLABS – Q3 FY26 Earnings Call – 23-Jan-26

LAURUSLABS: ARV-led generics and CDMO drive 15–25% growth, but biotech drag limits upside. EBITDA margins (26–28%) hinge on utilization and FX gains; ROCE recovery (18.5%→20–22%) rests on asset turnover. Gross margin at 60% needs ARV/CDMO mix, with risk of 55% under price pressure.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: CDMO grows 20% YoY (FY27), ARV stabilizes at ₹2,600 crore, peptide/ADC revenues commence in FY28 (~₹200–300 crore).
Outcome: Revenue CAGR of 18–22% (FY26–28), EBITDA margins at 26–28%, ROCE improves to 20–22%. CAPEX absorption drives asset turnover to 1.1x by FY28; net debt/EBITDA at 1.0–1.2x.

DRREDDY – Q3 FY26 Earnings Call – 21-Jan-26

Dr.Reddy’s topline growth hinges on Semaglutide/Abatacept execution and EM resilience, while margins face structural pressure from Lenalidomide exit, FX, and biosimilar delays; base case implies 6–8% revenue growth with 24–26% EBITDA, but bear-case risks skew asymmetric.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Semaglutide launches in Canada (May 2026, $50/unit) and India (March 2026, $30/unit), contributing $150–200M revenue. Abatacept EU approval (July 2027) and US Rituximab re-inspection (H1CY27) proceed as guided. EM grows 20% YoY; India sustains 15%+ organic growth. EBITDA margins recover to 24–26% on cost controls. Implication: 6–8% revenue growth; 10–12% EPS growth.